Regoli D, Drapeau G, Rovero P, Dion S, D'Orléans-Juste P, Barabé J
Eur J Pharmacol. 1986 Apr 9;123(1):61-5. doi: 10.1016/0014-2999(86)90687-4.
The newly discovered bradykinin antagonist [Thi5,8,D-Phe7]Bradykinin, supplied by J.-M. Stewart and three other compounds, [D-Phe7]BK, [Thi5,8,D-Phe7]Bradykinin and [Thi6,9,D-Phe8]Kallidin synthesized in our laboratory, were tested for their ability to antagonize bradykinin in four B2 receptor systems, the guinea-pig ileum, the rabbit jugular vein, the dog carotid artery and the dog urinary bladder as well as against desArg9-bradykinin in the rabbit aorta (a B1 receptor system). [D-Phe7]Bradykinin is a partial agonist, while [Thi5,8,D-Phe7]Bradykinin and [Thi6,9,D-Phe8]Kallidin are pure antagonists, the second one showing little BK-like activity on three of the four preparations. The kallidin analogue is more potent in all preparations than the bradykinin one. The two [Thi5,8,D-Phe7]BK (that supplied by J.-M. Stewart and that prepared in our laboratory) show very similar affinities in all preparations. The bradykinin analogue as well as the kallidin one are also active against desArg9-bradykinin in the rabbit aorta, at concentrations similar to those active on B2 receptor systems. The kinin antagonists are however specific for the kinins, since they do not interfere with the myotropic effects of angiotensin or substance P (SP) in the various preparations.
新发现的缓激肽拮抗剂[Thi5,8,D-Phe7]缓激肽由J.-M. Stewart提供,以及其他三种化合物,即[D-Phe7]BK、[Thi5,8,D-Phe7]缓激肽和我们实验室合成的[Thi6,9,D-Phe8]胰激肽,在四种B2受体系统(豚鼠回肠、兔颈静脉、犬颈动脉和犬膀胱)中测试了它们拮抗缓激肽的能力,以及在兔主动脉(一种B1受体系统)中对抗去精氨酸9-缓激肽的能力。[D-Phe7]缓激肽是一种部分激动剂,而[Thi5,8,D-Phe7]缓激肽和[Thi6,9,D-Phe8]胰激肽是纯拮抗剂,后者在四种制剂中的三种上显示出很少的BK样活性。胰激肽类似物在所有制剂中比缓激肽类似物更有效。两种[Thi5,8,D-Phe7]BK(由J.-M. Stewart提供的和我们实验室制备的)在所有制剂中显示出非常相似的亲和力。缓激肽类似物以及胰激肽类似物在兔主动脉中对去精氨酸9-缓激肽也有活性,其浓度与在B2受体系统上有活性的浓度相似。然而,激肽拮抗剂对激肽具有特异性,因为它们不会干扰各种制剂中血管紧张素或P物质(SP)的肌性效应。